NeoStem's Vice President of Clinical Development and Regulatory Affairs to Present at Two Venues This Week

NeoStem's Vice President of Clinical Development and Regulatory Affairs to
Present at Two Venues This Week

NEW YORK, Feb. 4, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS)
("NeoStem" or the "Company"), an emerging leader in the fast growing cell
therapy market, today announced that Jonathan Sackner-Bernstein, M.D., the
Company's Vice President of Clinical Development and Regulatory Affairs, will
present at two conferences this week.

FDA Public Hearing on Creating Alternative Pathway for Certain Drugs and
Biologics Intended to Address Unmet Medical Need

  oDate: Monday, February 4, 2013, 1:40 PM EST
  oVenue: FDA White Oak Campus, Silver Spring, MD


  oDate: Friday, February 8, 2013
  oVenue: Singularity University, NASA Research Park, Moffett Field, CA
  oSession 1: "A Path for Stem Cell Advances – Simplicity as Elegant,
    Achievable and Available" within "Regenerative Medicine: Stem Cells &
    Beyond" track at 8:45 AM, PST
  oSession 2: "Regulatory Innovation GPS (Guide to Promising Signs) for
    Development of New Medical Therapies" within "The Future of Medical
    Practice" track at 4:45 PM, PST

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell
therapy, capitalizing on the paradigm shift that we see occurring in medicine.
In particular, we anticipate that cell therapy will have a significant role in
the fight against chronic disease and in lessening the economic burden that
these diseases pose to modern society. We are emerging as a technology and
market leading company in this fast developing cell therapy market. Our
multi-faceted business strategy combines a state-of-the-art contract
development and manufacturing subsidiary, Progenitor Cell Therapy, LLC
("PCT"), with a medically important cell therapy product development program,
enabling near and long-term revenue growth opportunities. We believe this
expertise and existing research capabilities and collaborations will enable us
to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the
development of proprietary cell therapy products. NeoStem's most clinically
advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC
("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell
therapy for the treatment of cardiovascular disease and is enrolling patients
in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart
function after a heart attack. Athelos Corporation ("Athelos"), which is
approximately 80%-owned by our subsidiary, PCT, is collaborating with
Becton-Dickinson in the early clinical exploration of a T-cell therapy for
autoimmune conditions. In addition, pre-clinical assets include our
VSEL^TMTechnology platform as well as our mesenchymal stem cell product
candidate for regenerative medicine. Our service business and pipeline of
proprietary cell therapy products work in concert, giving us a competitive
advantage that we believe is unique to the biotechnology and pharmaceutical
industries. Supported by an experienced scientific and business management
team and a substantial intellectual property estate, we believe we are well
positioned to succeed.

For more information on NeoStem, please visit

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of this
press release, and involve certain risks and uncertainties. Forward-looking
statements include statements herein with respect to the successful execution
of the Company's business strategy, including with respect to the Company's or
its partners' successful development of AMR-001 and other cell therapeutics,
the size of the market for such products, its competitive position in such
markets, the Company's ability to successfully penetrate such markets and the
market for its contract development and manufacturing business, and the
efficacy of protection from its patent portfolio, as well as the future of the
cell therapeutics industry in general, including the rate at which such
industry may grow. The Company's actual results could differ materially from
those anticipated in these forward- looking statements as a result of various
factors, including but not limited to matters described under the "Risk
Factors" in the Company's Annual Report on Form 10-K filed with the Securities
and Exchange Commission on March 20, 2012 and in the Company's other periodic
filings with the Securities and Exchange Commission, all of which are
available on its website. The Company does not undertake to update its
forward-looking statements. The Company's further development is highly
dependent on future medical and research developments and market acceptance,
which is outside its control.

CONTACT: Trout Group
         Lauren Kwiecinski, Senior Associate
         Phone: +1-646-378-2934

NeoStem Inc. Logo
Press spacebar to pause and continue. Press esc to stop.